Tomas Kiselak - Jun 14, 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Tomas Kiselak
Stock symbol: VRDN
Transactions as of: Jun 14, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/16/2023, 07:54 PM
Previous filing: Jun 10, 2022
Next filing: Jun 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Award	$0	+20K		$0.00	20K	Jun 14, 2023	Common Stock	20K	$27.67	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.
F2	Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.